Neuronal loss alongside altered energy metabolism, are key features of Huntington's disease (HD) pathology. The orexigenic gut-peptide hormone ghrelin is known to stimulate appetite and affect whole body energy metabolism. Liraglutide is an efficient anti-type 2 diabetes incretin drug, with neuroprotective effects alongside anorectic properties. Combining liraglutide with the orexigenic peptide ghrelin may potentially promote brain/cognitive function in HD. The R6/2 mouse model of HD exhibits progressive central pathology, weight loss, deranged glucose metabolism, skeletal muscle atrophy and altered body composition. In this study, we targeted energy metabolism in R6/2 mice using a co-administration of liraglutide and ghrelin. We investigated their effect on brain cortical hormone-mediated intracellular signalling pathways, metabolic and apoptotic markers, and the impact on motor function in HD. We here demonstrate that liraglutide, alone or together with ghrelin (subcutaneous daily injections of 150 µg/kg (ghrelin) and 0.2 mg/kg (liraglutide), for 2 weeks), normalized glucose homeostatic features in the R6/2 mouse, without substantially affecting body weight or body composition. Liraglutide alone decreased brain cortical active GLP-1 and IGF-1 levels in R6/2 mice, alongside higher ADP levels. Liraglutide plus ghrelin decreased brain insulin, lactate, AMP and cholesterol levels in R6/2 mice. Taken together, our findings encourage further studies targeting energy metabolism in HD.
Huntington's disease (HD) is an autosomal dominant polyglutamine expansion disease 1 , associated with neuronal loss 2 . In addition, HD is associated with peripheral pathology, including weight loss and muscle atrophy [3] [4] [5] . Energy metabolism alterations in HD are likely to contribute to neurodegenerative processes 6 . Mitochondrial dysfunction and widespread changes in energy metabolism have been suggested as underlying key players in HD pathogenesis 7 . Studies in HD models indicate that mutant huntingtin (HTT) disrupts mitochondrial bioenergetics and adenosine triphosphate (ATP) generation 8, 9 . A dysfunctional central energy metabolism is thought to promote neurodegenerative processes in HD 10 . This is in line with growing evidence demonstrating that many neurodegenerative disorders are metabolic diseases, mediated by impairments in brain energy metabolism, including insulin responsiveness and glucose utilization (reviewed in 11, 12 ). Therefore, targeting mechanisms underlying metabolic alterations could be beneficial, not only for metabolic features, but also for neuronal function.
Liraglutide in combination with ghrelin moderately affects R6/2 mouse brain cortical intracellular signalling. To assess the possible effects of liraglutide and ghrelin on brain cortical signalling, we assessed cortical levels of GLP-1, insulin, IGF-1 and insulin receptor density. Despite no significant changes in active GLP-1 levels, 2.3-and 2.2-fold higher insulin (P = 0.045) and IGF-1 levels (P = 0.0045) were found in R6/2 mouse cortex compared to WT littermates (Fig. 1a-c) . Despite no significant differences between these cohorts in Table 1 . Effect of liraglutide plus ghrelin on blood biochemical features in 12-week old R6/2 mice. Data are mean ± SEM of the indicated number of mice/group. Statistical significance: *P < 0.05, **P < 0.01 vs. salinetreated WT mice; and £ P < 0.05, ££ P < 0.01 vs. saline-treated R6/2 mice, by one-way ANOVA, with Tukey or Sidak post-hoc tests for multiple comparisons (for a Gaussian distribution), or with the Kruskal-Wallis test, with Dunn post-test (non-Gaussian distribution).
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Liraglutide administration per se decreased R6/2 mouse brain cortical active GLP-1 (4.2-fold, P = 0.0094) and IGF-1 levels (1.9-fold, P = 0.0045) compared to vehicle treated R6/2 mice (Fig. 1a,c) .
Co-administration of liraglutide and ghrelin appeared to exert distinct effects, since the even lower brain insulin levels in R6/2 mice (by 1.8-fold, P = 0.045) compared to vehicle treated mice (Fig. 1b) were not followed by significant changes in the remaining hormones levels (Fig. 1a,c) .
Liraglutide in combination with ghrelin moderately affects glycolysis and energy metabolism in R6/2 mouse brain cortex. Brain energy metabolism has been shown to be altered in R6/2 mice 26 . We therefore evaluated the possible effects of liraglutide and ghrelin on tricarboxylic acid cycle-and energy metabolism-related parameters in cortex from R6/2 mice and WT mice.
In this study, R6/2 mice exhibited a 4-fold decrease in ADP levels (P = 0.0234) along with a 5.3-fold increase in ATP/ADP ratio (P = 0.0316), which were both normalized by 2 weeks of liraglutide administration (P = 0.0221 and P = 0.026, respectively) (Fig. 2d,f) . Despite no significant changes in brain cortical glucose, pyruvate, lactate, ATP or AMP levels in vehicle treated R6/2 mice compared to WT littermates ( Fig. 2a-d, g,h) , co-administration of liraglutide and ghrelin induced a 1.6-fold and a 35-fold decrease in both lactate (P = 0.03) and AMP (P < 0.0001) levels (Fig. 2c,g ), and improved the brain energy status by 2-fold (P < 0.0001) (Fig. 2h) , suggesting a decrease in cortical catabolic pathways.
Liraglutide in combination with ghrelin normalize brain triglyceride, and cholesterol levels in R6/2 mice. The cholesterol biosynthetic pathway has been shown to be impaired in HD, with alterations in cholesterol and triglycerides levels 27 . Regarding the possible use of triglycerides, free fatty acids (FFA) and cholesterol as alternative brain metabolic substrates, we observed that, although not significant, there was a trend towards a change in brain cortical triglyceride, cholesterol and FFA levels. Cortical triglyceride and cholesterol levels were ~3-and ~5-fold higher (P = 0.1555 and P = 0.0985) in saline-treated R6/2 mice, whereas their brain FFA were ~3 times lower (P = 0.8611) than in WT littermates ( Fig. 3a-c ). Liraglutide per se or upon co-administration with ghrelin normalized brain triglyceride and cholesterol levels to nearly those of WT mice (Fig. 3a,c) . These results suggest that liraglutide, alone or co-administrated with ghrelin, may attenuate the use of triglycerides and cholesterol as brain alternative metabolites.
Effect of liraglutide in combination with ghrelin on R6/2 mouse brain cortical apoptotic pathways.
Low levels of brain caspase activity have been shown to affect axonal function 28 , and cognitive deficits 29 , whereas increased caspase activity may lead to inhibition of autophagy 30, 31 . We therefore investigated the effects of liraglutide and ghrelin on caspase activities in R6/2 and WT mice brain cortex.
A 2-fold increase in brain cortical Caspase-10-like activity was found in vehicle treated R6/2 compared to WT mice, while no significant changes were observed for the other initiator Caspases-1-, -2-, -8-, -9-like activities ( Fig. 4a-f ). These may account for unchanged Caspase-3 mRNA and Caspase-3 enzyme activity (Fig. 4g,h) , and Caspase-6-like activity (Fig. 4i) under these conditions. The 2-fold stimulation of Caspase-6-like activity induced by liraglutide per se in R6/2 mouse brain (Fig. 4i) was not accompanied by significant changes in the remaining Caspase-like activities or mRNA under these conditions.
Co-administration of liraglutide plus ghrelin resulted in a 1.3-fold stimulation of brain cortical Caspase-12-like activity in R6/2 mice (Fig. 4c,f ) that, nonetheless, had no significant impact on the activities of the effector Caspases-3 and -6-like (Fig. 4h,i) .
Liraglutide in combination with ghrelin does not affect motor and exploratory activities in R6/2 mouse. Motor deficits along with a clasping behaviour phenotype are main features of HD mouse models, which progress with the disease 32, 33 . However, in this study we could not find any significant differences between experimental groups in terms of the locomotor and exploratory activity parameters evaluated during the open-field test (Fig. 5a-e) , nor in R6/2 mice after liraglutide and ghrelin co-administration (Fig. 5a,c) . However, an increase in paw clasping to a score of 2 was observed in vehicle-treated R6/2 mice compared with WT mice ( Table 2 ) that, nonetheless, was not significantly changed by liraglutide alone or in combination with ghrelin ( Table 2 ).
Discussion
Accumulating evidence over the last decade supports the concept of HD being a metabolic disorder. Animal studies have demonstrated that targeting peripheral energy metabolism might have beneficial effects on both central and peripheral pathology in HD 3, 17 . HD is associated with progressive weight loss and a lower body mass index (BMI), and a higher BMI has been shown to correlate with slower disease progression 34 . As a catabolic state is present in human HD 35, 36 and HD mouse models 32 , this suggests that normalization of energy metabolism might be beneficial.
The R6/2 mouse model is the most widely used model of HD 32 , replicating many features seen in human patients, including weight loss due to increased energy metabolism 37 . We recently showed that chronic ghrelin administration for 4 weeks postpones R6/2 mouse weight loss by one week 38 . Administration of the GLP-1 analogue, liraglutide, has been shown to be associated with weight loss 22, 39 , which could be problematic if used in a mouse model displaying weight loss, such as the R6/2 mouse. However, we here demonstrate that daily injections of either liraglutide alone or together with ghrelin for 2 weeks (from 10 to 12 weeks of age) did not further decrease body weight in R6/2 mice. Body composition alterations seen in R6/2 mice 40 , such as lower fat mass, was further decreased with liraglutide administration alone, while no changes were found in liraglutide and ghrelin treated R6/2 mice. : n = 9 WT, n = 9 R6/2, n = 6 R6/2 + Lira, n = 9 R6/2 + Lira + Ghr. Figure  b : n = 8 WT, n = 10 R6/2, n = 9 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure c: n = 9 WT, n = 10 R6/2, n = 9 R6/2 + Lira, n = 7 R6/2 + Lira + Ghr. Figure d : n = 6 WT, n = 7 R6/2, n = 5 R6/2 + Lira, n = 6 R6/2 + Lira + Ghr. , AMP (g) and energy charge (h). ADP level was significantly decreased (e), while the ATP/ADP ratio (f) was significantly increased in the cortex of 12 weeks old vehicle treated R6/2 mice compared to WT littermates. Liraglutide treatment alone normalized cortical ADP levels and ATP/ADP ratio, while liraglutide together with ghrelin lowered AMP (g) and lactate levels (c) and increased the energy charge (h) in R6/2 mice compared to WT littermates. Data are mean ± SEM of the indicated number of mice/group. Statistical significance: *P < 0.05, **P < 0.01, ****P < 0.0001, by one-way ANOVA, with Tukey, Sidak or unprotected Fisher's LSD post-hoc tests for multiple comparisons (for a Gaussian distribution) (a-d,g,h), or with the Kruskal-Wallis test, with Dunn post-test (non-Gaussian distribution) (e., f). [Figure a: n = 9 WT, n = 8 R6/2, n = 8 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure b: n = 9 WT, n = 7 R6/2, n = 10 R6/2 + Lira, n = 7 R6/2 + Lira + Ghr. Figure c: n = 10 WT, n = 10 R6/2, n = 7 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure d : n = 10 WT, n = 10 R6/2, n = 10 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure e: n = 7 WT, n = 7 R6/2, n = 10 R6/2 + Lira, n = 6 R6/2 + Lira + Ghr. Figure f: n = 6 WT, n = 7 R6/2, n = 10 R6/2 + Lira, n = 8 R6/2 + Lira + Ghr. The choice of a 2-week treatment with ghrelin and liraglutide was based on our previous study on the effects of a 2-and a 4-week treatment with ghrelin in R6/2 mice skeletal muscle 38 . Although a 2-week administration of ghrelin did not change R6/2 mice body weight or their peripheral type 2 diabetes features 38 , this was sufficient to reverse the expression of catabolic genes (e.g. Caspase 8, Creb1 and Traf-5) and muscle morphology, as well as to rescue their nest building defects 38 . Metabolic effect of drug treatment can of course be related to possible alterations in food intake. It has previously been shown that R6/2 mice display increased food intake in comparison to WT littermates 37 . In our 2-week study there was no change in food intake comparing treated groups, however a decreased food intake in comparison to WT littermates could be noted during a few days of treatment period. Since food consumption was similar the majority of days, food consumption-induced differences should be marginal. However, of course this should be considered when interpreting results.
Although hyperglycaemia along with reduced insulin levels has been shown previously in R6/2 mice 23 , in the present study we found that elevated levels of serum glucose were accompanied by normal insulin levels, increased HOMA-IR and decreased HOMA-β in R6/2 mice compared to WT littermates. This may be explained by the fact that our R6/2 mice presented an early to middle stage disease phenotype and, thus, insulin production was not dramatically affected yet. This was in line with previous studies demonstrating a variation in disease progression depending on the CAG repeat size 41, 42 . Activation of the GLP-1 receptor by liraglutide and other analogues, such as exendin-4, has been shown to exert anti-diabetic effects, by improving pancreatic β-cell function and glucose regulation in HD mouse models 17, 43 . Conversely, studies involving the effect of ghrelin administration on insulin secretion β-cell in other rodent and in vitro models have given contradictory results, with both inhibitory 44 and beneficial effects 45 . In the present study, liraglutide injected alone or together with ghrelin normalized peripheral basal glucose levels and both HOMA-β and HOMA-IR (two mathematical models widely used to evaluate β-cell function and insulin resistance, respectively, from fasting glycemia and insulin or C-peptide levels 24, 25 ) in R6/2 mice, suggesting a beneficial effect on glucose homeostasis, insulin resistance and pancreatic β-cell function.
Mitochondrial dysfunction and oxidative stress have been shown to contribute to R6/2 mouse central pathology, probably resulting from elevated insulin/IGF-1 signalling pathways and subsequent progression of neurodegeneration 46 . Conversely, others have suggested that a compensatory increase in brain insulin levels may overcome systemic insulin resistance in R6/2 mice 47 . In line with the observed peripheral insulin resistance, elevated brain insulin levels in our R6/2 mice were normalized after 2 weeks of co-administration of liraglutide and ghrelin. Decreased brain cortical active GLP-1 and IGF-1 levels after liraglutide administration in R6/2 mice suggested that an activation of compensatory mechanisms could occur to overcome their lower brain hormone levels and maintain downstream cAMP-and/or ERK1,2-mediated signalling pathways.
The unchanged brain cortical ATP levels in vehicle treated R6/2 mice was in line with previous studies in HD mice [48] [49] [50] and early stage HD patients 51 . This reinforced the idea that, though mutant HTT may hamper brain glycolysis, it may not directly affect mitochondrial oxidative phosphorylation, thus preserving ATP synthesis 48, 49 . Since the later depends mostly on ADP levels, the maintenance of ATP levels in vehicle treated R6/2 mouse may occur at the expense of brain ADP and AMP levels 52 . This may be accompanied by an increment in total creatine levels (creatine plus phosphocreatine, an alternative source of ATP) 52 . Of note, Mochel et al. 24 found that striatal ATP and phosphocreatine levels were inversely correlated with the number of CAG repeats in HD mice. Alternatively, we cannot exclude that the decreased brain ADP and AMP in vehicle treated R6/2 mice may arise from the maintenance of their cAMP and/or of adenosine levels, a critical molecule in neurotransmission and energy metabolism, whose increased extracellular content was beneficial in R6/2 mouse brains 53 . More recently, Kao et al. (2016) 54 suggested that a compensatory biphasic regulation of striatal adenosine tone in HD rodents may arise with disease progression. This may be accompanied by an increased expression and activity of striatal adenosine kinase in late-stage R6/2 mice, ultimately converting adenosine into AMP or inosine and thereby decreasing its levels 54 . Additionally, the tendentiously lower brain cortical lactate and ATP levels, and higher ADP levels associated with subcutaneous liraglutide treatment in R6/2 mice suggested that it may not only partially inhibit their brain glycolysis and energy metabolism, but the lower amount of ATP formed may be also used to further yield ADP and cAMP, thus maintaining their intracellular pools.
Caspases are pivotal players in both apoptosis and autophagy, controlling the turnover of protein aggregates and elimination of damaged cells 55 . However, Caspases-3 and -6 were also found to play other non-apoptotic roles in the CNS 56 . The significant increase in brain Caspase-10-like activity of vehicle treated R6/2 mice compared to WT littermates was not significantly affected by either liraglutide alone or in combination with ghrelin. Despite no significant changes in Caspase-6-like or Caspase-12-like activities in vehicle treated R6/2 mice, liraglutide alone significantly increased Caspase-6-like activity, and in combination with ghrelin stimulated Caspase-12-like activity in R6/2 mice. This could indicate that both liraglutide alone or co-administered with ghrelin may exert some neuroprotection in HD. Unchanged Caspase-3 mRNA expression, and Caspase-3 and -6-like activity suggests that caspase-mediated apoptosis may not be involved in R6/2 mouse neuronal death and locomotor deficits.
Although R6/2 mice display progressive motor dysfunction 30, 31 , there were no effects on their motor dysfunction in the present study, evaluated by open field and paw clasping behaviour testing. This could have several reasons but, most likely, the short treatment time was not long enough to translate into functional motor-cognitive recovery. Hence, further studies using longer treatment strategies, possibly starting at an earlier age, are encouraged.
In conclusion, our data demonstrate beneficial effects of liraglutide alone and in combination with ghrelin on peripheral glucose homeostasis in R6/2 mice. Co-administration of liraglutide and ghrelin decreased brain cortical insulin, lactate, AMP and cholesterol levels in R6/2 mice, while liraglutide alone decreased brain cortical active GLP-1 and IGF-1 levels in R6/2 mice, alongside higher ADP levels.
Our results support further studies targeting (brain) energy metabolism, which might exert beneficial effects on HD progression. Evaluating underlying effects of liraglutide and ghrelin administration in HD are warranted.
Material and Methods
Animals. All experimental procedures performed on mice were carried out in accordance with the approved guidelines in the ethical permit approved by The Malmö/Lund Animal Welfare and Ethics Committee (ethical permit number: M5-15).
Male transgenic R6/2 HD mice (expressing exon 1 of the HD gene) 33 and their wild-type (WT) littermates were used. Mice were obtained through crossing heterozygous R6/2 males with WT Females (F1 of CBAxC57BL/6 J). Tail tips were sent on dry ice to Laragen (Laragen Inc., CA, USA) for CAG repeat length determination, by polymerase chain reaction assay. The R6/2 mice used in this study had a CAG repeat size ranging from 275-312. The CAG repeat size of our R6/2 colony, results in a disease progression slower than that of the R6/2 mouse with 150 CAG repeats, as described by Morton and co-workers in 2009 57 . In our colony, 18-week old R6/2 mice correspond to overt disease (with robust changes in CSF Neurofilament light chain levels and striatal volume and body weight changes 58 ), and 12-week old R6/2 mice correspond to late premanifest disease (similar to what is described by Morton et al. 57 . No significant exploratory and locomotor behavior was seen in 12 weeks old R6/2 mice compared to WT littermates, and no significant improvement was seen after 2 weeks administration of either liraglutide alone or together with ghrelin. Data are mean ± SEM of the indicated number of mice/group. Statistical significance was given by the one-way ANOVA, with unprotected Fisher's LSD post-hoc tests for multiple comparisons (for a Gaussian distribution) (a). [Figure a: n = 10 WT, n = 10 R6/2, n = 11 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure b : n = 7 WT, n = 9 R6/2, n = 10 R6/2 + Lira, n = 7 R6/2 + Lira + Ghr. Figure c: n = 7 WT, n = 8 R6/2, n = 10 R6/2 + Lira, n = 7 R6/2 + Lira + Ghr. Figure d : n = 9 WT, n = 11 R6/2, n = 10 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr. Figure e: n = 10 WT, n = 9 R6/2, n = 10 R6/2 + Lira, n = 10 R6/2 + Lira + Ghr].
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Food consumption was monitored daily from 11 weeks of age (mice grouped per genotype and 1-3 animals per cage) during 2 weeks of ghrelin and liraglutide administration, by measuring the difference between the pre-weighed chow food and the weight of chow after 24 h. Mice had ad libitum access to water and food.
At the end of the 2-week treatment, mice were fasted for ~6 h (starting late in the evening) and afterwards body composition was measured using the Lunar Prodigy dual energy x-ray absorptiometry (DEXA; GE Lunar Corp., Madison, WI) and thereafter mice were euthanized, blood was collected and brain was dissected. Tissue samples were snap-frozen in liquid nitrogen and stored at −80 °C until further use. Serum obtained from blood samples was collected by centrifugation at 2000 × g, for 10 min, at 4 °C, and immediately frozen to −80 °C. Serum Analyses. Serum glucose levels were measured using the glucose oxidase method (Infinity Glucose Hexokinase Kit, Thermo Scientific, Middletown, VA, USA), and levels of insulin were determined by the Mercodia Mouse Insulin ELISA Kit (Uppsala, Sweden). The homeostatic model assessment (HOMA) was calculated to measure insulin resistance (IR) and pancreatic beta-cell function (β). HOMA-IR was calculated as follows: (Insulin X Glucose)/22.5, and HOMA-β as follows: (20 × Insulin)/(Glucose − 3.5) 24 .
Isolation and Preparation of Brain Cortical Homogenates.
Mice were weighed and euthanized by decapitation, and brains were immediately removed. Brain cortices were immediately dissected and snap-frozen for further studies. Immediately before the experiments, brain cortices were homogenized at 0-4 °C in lysis buffer, containing (in mM) the following: 25 HEPES, 2 MgCl 2 , 1 EDTA, 1 EGTA, (pH 7.4), supplemented with 2 mM DTT, 100 μM PMSF, and commercial protease and phosphatase inhibitors cocktails. The homogenate was centrifuged at 17,968 × g for 10 min, at 4 °C, in a Sigma 2-16 K centrifuge to remove the nuclei, and the resulting supernatant was collected. The pellet was further resuspended in supplemented buffered solution and centrifuged again at 17,968 × g for 10 min, at 4 °C. The supernatant was added to the previously obtained one and protein content was measured using Pierce BCA Assay Kit (Thermo Scientific, Rockford, IL, USA) according to manufacturer's protocol.
Quantification of Pivotal GLP-1/Insulin/IGF-1 Signalling Markers' Levels. Brain cortical GLP-1/ Insulin/IGF-1-mediated signalling pathways were analysed by the determination of the pivotal molecules: active GLP-1, insulin, IGF-1 and cAMP using commercially available ELISA kits, according to manufacturers' instructions with slight modifications.
Active GLP-1 levels were measured in 5 μL of each brain cortical homogenate (working dilution of 1:5) by the Fluorescent ImmunoAssay kit for Active GLP-1 (7-36) Amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) Ultra-sensitive (Phoenix Pharmaceuticals, Inc; Karlsruhe, Germany). Fluorescence was determined using an excitation and emission wavelengths of 325 and 420 nm, respectively, in a SpectraMax Gemini EM multiplate fluorescence reader. Results were expressed as pg/mL/mg protein.
Brain cortical insulin levels were measured in 10 μL of each brain cortical homogenate, by using the above mentioned Mercodia Mouse Insulin ELISA Kit. Results were expressed as pg/mL/mg protein.
Brain cortical IGF-1 levels were measured in 5 μL of each brain cortical homogenate (working dilution of 1:20) by the Rat IGF-1 ELISA kit (Biosensis Pty Ltd; Thebarton, South Australia). Absorbance was read at 450 nm, in a SpectraMax Plus 384 microplate reader. Results were expressed as pg/mL/mg protein.
cAMP levels were determined in 7.5 μL of each brain cortical homogenate (working dilution of 1:10) with the cAMP Direct Immunoassay Kit (Colorimetric) (BioVision; Milpitas, CA, USA). Absorbance was read at 450 nm, in a Biochrom Asys Expert 96 UV Microplate Reader (Cambourne, Cambridge, UK). Results were expressed as pmol/mg protein.
Relative PKA activity was determined in 5 μL of each brain cortical homogenate (working dilution of 1:6) by the PKA kinase activity kit (Enzo Life Sciences, Farmingdale, NY, USA). The absorbance was determined at 450 nm, in a SpectraMax Plus 384 multiplate reader. Results were expressed as ng/µL/mg protein.
Western Blot Analyses. Samples containing denatured brain cortical homogenates (25 μg per lane) were subjected to sodium dodecyl sulphate (SDS)/polyacrylamide gel electrophoresis (SDS/PAGE) (8-15%) and transferred onto polyvinyl difluoride (PVDF) membranes. Then, membranes were blocked for 1 h at room temperature in Tris-buffered saline (TBS, pH 7.4) plus 1 or 5% nonfat dry milk or bovine serum albumine (BSA), plus 0.05% Tween 20. Membranes were then incubated overnight at 4 °C with rabbit IRβ (4B8) (1:1000) or rabbit Phospho-ERK1/2 (Thr202/Tyr204) (1:1000) ( Supplementary Fig. 3 ) primary antibodies (all from Cell Signaling Technology; Leiden, The Netherlands). Membranes were then incubated with the respective anti-rabbit secondary IgG antibodies (1:10,000), for 2 h at room temperature, and developed using ECF. Immunoreactive bands were visualized by the VersaDoc Imaging System (Bio-Rad, Hercules, CA, USA). Fluorescence signal was analysed using the QuantityOne software and the results given as INT/mm 2 . Of note, membranes were then re-probed with the corresponding mouse β-actin (1:5000; from Sigma, St. Louis, MO, USA) or rabbit Total ERK (1:1000; from Cell Signaling Technology; Leiden, The Netherlands) primary antibodies. Results were presented as phosphorylated protein/total protein or protein levels (corresponding to the ratio of each protein vs. β-actin).
Assessment of Brain Glucose Levels. Brain glucose levels were determined by the above mentioned glucose oxidase method (Infinity Glucose Hexokinase Kit, Thermo Scientific, Middletown, VA, USA), in 3 µL of each brain cortical homogenate. Results were expressed as nmol/L/mg protein.
Measurement of Brain Glycolysis Markers' Levels. Pyruvate levels were determined by the Pyruvate Colorimetric/Fluorometric assay kit (BioVision; Milpitas, CA, USA), according to manufacturer's instructions, in 5-10 µL of each brain cortical homogenate. Fluorescence was determined using an excitation and emission wavelengths of 535 and 590 nm, respectively, in a SpectraMax Gemini EM multiplate fluorescence reader. Results were expressed as pmol/mg protein.
Lactate levels were determined by the Lactate Colorimetric/Fluorometric assay kit (BioVision; Milpitas, CA, USA), according to manufacturer's instructions, in 5 µL of each brain cortical homogenate. Fluorescence was determined using an excitation and emission wavelengths of 535 and 590 nm, respectively, in a SpectraMax Gemini EM multiplate fluorescence reader. Results were expressed as pmol/mg protein.
Determination of Brain Adenine Nucleotides' Levels. Brain cortical homogenates (5 µL/sample, further diluted into 30 µL saline solution) were assayed for adenine nucleotides (ATP, ADP and AMP) by separation in a reverse-phase HPLC, as described by Stocchi et al. 60 . The HPLC apparatus was a Beckman-System Gold, consisting of a 126 Binary Pump Model and 166 Variable UV detector controlled by a computer. The detection wavelength was 254 nm, and the column was a Lichrospher 100 RP-18 (5 µm) from Merck (Darmstadt, Germany). An isocratic elution with 100 mM phosphate buffer (KH 2 PO 4 ; pH 6.5) and 1.0% methanol was performed with a flow rate of 1 mL/min. The required time for each analysis was 6 min. Adenine nucleotides (ATP, ADP and AMP) were identified by their chromatographic behavior (retention time, absorption spectra, and correlation with standards). Results were presented as µmol/mg protein. Adenylate energy charge was determined according to the following formula: (ATP + 0.5 ADP)/(ATP + ADP + AMP).
